Psychedelic Drugs Market Growth and Industry Forecast
The global psychedelic drugs market is projected at US$4.1 Bn in 2025 and expected to reach US$9.5 Bn by 2032, registering a robust CAGR of 12.9% over the forecast period 2025-2032.
Psychedelic Drugs Market: Key Insights & Trends
- LSD leads product type with 38.4% share in 2025, driven by microdosing adoption.
- Psilocybin is the fastest-growing product, supported by 80% depression remission in trials.
- Depression dominates therapeutic indications with a 32.6% share due to unmet treatment needs.
- PTSD is the fastest-growing indication, fueled by MDMA trials showing 67% remission.
- Oral administration holds a 42.6% share in 2025, favored for convenience and affordability.
- Synthetic psychedelics lead by origin with 55% share, backed by scalability and patent protection.
- North America commands a 39.7% share, supported by FDA designations and state decriminalization.
- Asia Pacific grows fastest at 16% CAGR, led by Japan and India with policy subsidies.
Key Growth Drivers
- Increasing Prevalence of Mental Health Disorders
The psychedelic drugs market is gaining momentum with rising mental health concerns, as the WHO noted over 970 million cases globally in 2019, a number set to grow post-pandemic and with aging populations. In the U.S., 21% of adults faced mental illness in 2021, fueling demand for treatments such as psilocybin for depression. Traditional antidepressants fail for 30–40% of patients, creating space for psychedelic therapies addressing PTSD and anxiety. Advances in AI-supported personalized dosing improve outcomes, while rising healthcare spending strengthens investment. Regulatory tailwinds, including FDA breakthrough designations for MDMA in PTSD, accelerate commercialization, with approvals potentially adding billions in value by 2030.
- Growing Research and Clinical Trials
Advancements in psychedelic research are accelerating growth, with over 200 active clinical trials by 2025 exploring psilocybin and MDMA for treatment-resistant depression and PTSD. MAPS’ Phase 3 trials in 2024 showed 67% remission in PTSD patients with MDMA-assisted therapy, validating safety and efficacy and drawing $500 million in venture funding. Rising anxiety rates among millennials, combined with fast-tracked reviews from regulators such as the EMA, further support adoption. Technological innovations, including neuroimaging to monitor brain plasticity, are shortening development timelines by up to 30%. These trends are set to expand applications in neurology, driving trial-backed revenues at an estimated 15% annual pace, positioning the psychedelic drugs industry for deeper integration into mainstream healthcare.
- Regulatory Approvals and Policy Shifts
Policy shifts are reshaping the Psychedelic Drugs Market, with the FDA issuing 2025 guidance after Lykos Therapeutics’ MDMA resubmission showed 71% response rates in depression trials. Decriminalization in more than 10 U.S. states, including Oregon’s psilocybin program serving 3,000 patients annually, has reduced compliance costs by 25% for developers. Global mental health investments of $10 billion and UN-led reclassifications are fostering subsidies and cross-border collaborations, strengthening supply chains for natural psychedelics. These changes are lowering barriers, accelerating approvals, and supporting broader commercialization of therapies addressing conditions resistant to conventional treatments.
Key Restraints
- Stringent Regulatory Hurdles
The Psychedelic Drugs Market faces challenges from rigorous approval processes, as evidenced by the FDA's 2024 rejection of MDMA for PTSD due to trial design concerns, delaying commercialization by 1-2 years and increasing R&D costs by 40% for competitors. These hurdles limit market entry, particularly for Schedule I substances, creating bottlenecks in scaling production and threatening smaller players with compliance expenses exceeding US$100 million per drug.
- Supply Chain Bottlenecks and High Product Costs
Supply constraints in the Psychedelic Drugs Market arise from limited cultivation of natural sources such as psilocybin mushrooms, with global production capacity at under 500 kg annually per industry estimates, inflating costs to US$5,000-10,000 per treatment dose. Regulatory scrutiny on sourcing exacerbates issues, impacting competitors through volatile pricing and delays in therapeutic delivery.
Psychedelic Drugs Market Trends and Opportunities
- Emerging Technologies in Drug Delivery
Innovations such as intranasal and microdosing formulations are enhancing bioavailability, reducing side effects, and expanding access through non-invasive options suited for homecare. Emerging economies such as India, where 150 million people face mental health challenges, are boosting adoption with supportive programs such as the 2025 National Mental Health subsidies. These advances meet rising demand for affordable therapies, creating strong growth opportunities and broadening the therapeutic reach of psychedelic treatments.
- Supportive Policy Changes in Developing Economies
Policy reforms present opportunities in the Psychedelic Drugs Market, such as Brazil's 2025 decriminalization of ayahuasca derivatives, targeting a US$500 million sub-market for addiction treatment amid 20 million affected individuals. Unmet demand in South America and Africa, where 70% lack mental health access (WHO), aligns with subsidies under UN sustainable development goals, projecting 18% growth. Emerging collaborations with local regulators could integrate psychedelics into public health, fulfilling therapeutic gaps.
Segment-wise Trends & Analysis
LSD Holds Leading Share, Psilocybin Gains Momentum in Psychedelic Therapies
LSD leads with a s38.4% share in 2025, driven by microdosing protocols, while psilocybin is the fastest-growing, supported by strong trial efficacy in depression. Synthetic LSD offers scalability but faces patent expirations, whereas psilocybin benefits from improved extraction despite cultivation hurdles. A key challenge across both segments remains dose standardization, impacting broader therapeutic adoption.
- Hybrid compounds blend psychedelics for tailored effects.
- Regulatory nods accelerate psilocybin adoption.
- Supply innovations reduce costs by 15%.
- Market expansion targets anxiety applications.
Depression Drives Psychedelic Drug Demand, PTSD Expands Through Clinical Programs
Depression leads with a 32.6% share in 2025, driven by unmet needs in treatment-resistant cases, while PTSD is the fastest-growing, supported by veteran-focused trials showing strong remission. Opportunities stem from policy backing for opioid crisis therapies, though recruitment for niche indications such as addiction remains difficult. Integration with psychotherapy is a key trend improving treatment outcomes.
- Depression prevalence drives MDMA demand.
- PTSD programs expand in military health.
- Anxiety indications grow via microdosing.
- Narcolepsy applications face competition from stimulants.
Oral Administration Dominates Psychedelics, Injectables and Inhalation Gain Adoption
Oral routes dominate with 42.6% share in 2025, valued for clinical convenience, while injectables grow fastest due to rapid action in acute cases. Inhalation emerges for quick pain relief, though sterility remains a challenge for injectables. Expanding opportunities include home-use devices, enhancing accessibility and diversifying treatment delivery options.
- Oral benefits from low-cost production.
- Injectable faces supply chain hurdles.
- Intranasal innovations target 20% market.
- Transmucosal options enhance bioavailability.
Synthetic Psychedelics Lead Market, Natural and Hybrid Sources See Rising Demand
Synthetic leads with 55% share in 2025, backed by scalability and consistent output, while natural options grow on rising demand for plant-based psilocybin and sustainability appeal. Key challenges involve ethical sourcing, but biotech cultivation offers solutions. Hybrid origins emerge as a trend, balancing purity, supply reliability, and consumer preference.
- Synthetic dominates due to patent protection.
- Natural faces regulatory variability.
- Biotech advances blend origins.
- Market shifts toward eco-friendly sourcing
Regional Analysis
North America Leads the Psychedelic Drugs Market with Research Strength and Regulations
The Psychedelic Drugs Market exhibits varied regional dynamics, with North America commanding 39.7% global share in 2025 due to advanced research infrastructure and regulatory progress. Europe follows at 25%, bolstered by clinical collaborations, while Asia Pacific grows at 16% CAGR amid rising mental health awareness and policy liberalization in key countries.
U.S. Psychedelic Drugs Market – 2025 Snapshot & Outlook
The U.S. market, valued at US$1.8 Bn in 2025, is set to expand with FDA breakthrough designations for psilocybin and strong demand from 13 million veterans affected by PTSD. State decriminalization in Colorado and Oregon boosts licensed centers, while US$1 Bn in federal mental health funding improves reimbursement and reduces patient costs. Consumer openness to psychedelic therapy reaches 65%, and retail trends highlight telehealth integration, with online pharmacies growing rapidly to expand nationwide access. These drivers collectively strengthen adoption and accelerate long-term market growth.
- High PTSD incidence drives MDMA demand.
- FDA resubmissions boost investor confidence.
- 71% psilocybin response rate in trials (Johns Hopkins).
Europe Psychedelic Drugs Growth Backed by Research Hubs and Harmonized Regulations
Europe's Psychedelic Drugs Market grows steadily, led by research hubs in Germany and the U.K., where EU-funded trials address 84 million mental health cases. Trends focus on harmonized regulations under EMA, with France advancing ketamine clinics.
Germany Psychedelic Drugs Market – 2025 Snapshot & Outlook
Germany’s market, valued at $0.6 Bn in 2025, is set to reach US$1.4 Bn by 2032, driven by BfArM approvals for psilocybin in treatment-resistant depression impacting 5 million citizens. The 2025 Health Innovation Act enables 15% R&D deductions, boosting margins for local firms. Policy focus on integrative medicine expands clinics, while 55% physician acceptance and rising urban demand for holistic therapies, with 30% uptake, support growth momentum.
- Robust trial infrastructure aids MDMA adoption.
- EMA fast-track reduces approval times by 6 months.
- Chronic pain applications expand market by 20%.
U.K. Psychedelic Drugs Market – 2025 Snapshot & Outlook
The U.K. market, worth US$ 0.5 Bn in 2025, is projected to hit US$1.2 Bn by 2032, supported by MHRA backing for LSD microdosing in anxiety affecting 8 million people. The 2025 Mental Health Levy covers 25% of costs, expanding access, while NHS-integrated programs improve delivery. Decriminalized research fosters collaborations, with 60% patient interest driving adoption.
- Anxiety epidemic fuels oral route demand.
- Post-Brexit funding adds US$200 million.
- 70% efficacy in depression pilots (UCL trials).
Asia Pacific Psychedelic Drugs Market Accelerates with Cultural and Policy Shifts
Asia Pacific's Psychedelic Drugs Market accelerates, with Japan and India leading amid 370 million mental health cases (WHO, 2024). Trends emphasize cultural integration of traditional psychedelics and regulatory easing in South Korea.
Japan Psychedelic Drugs Market – 2025 Snapshot & Outlook
Japan's market totals US$0.4 Bn in 2025, projected to grow to US$1.0 Bn by 2032 at 14.1% CAGR, supported by PMDA approvals for ketamine in depression, affecting 5 million elderly (Ministry of Health, 2024). Drivers include aging demographics and 2025 subsidies under the National Health Policy, cutting treatment costs by 18% for insurers. Tax incentives for biotech R&D enhance competitiveness. A MHLW survey shows 50% clinician support for psilocybin trials (2024). Shifts to hospital-based delivery improve outcomes.
- Geriatric depression drives injectable use.
- Collaborative trials with U.S. firms.
- 65% response in anxiety studies (Kyoto University).
India Psychedelic Drugs Market – 2025 Snapshot & Outlook
India's market is US$0.3 billion in 2025, set to reach US$0.9 billion by 2032 at 16.7% CAGR, fueled by CDSCO pilots for MDMA in addiction, targeting 150 million cases (Ministry of Health, 2024). Supportive policies such as the 2025 Ayush Integration Act offer 20% subsidies, aiding rural access and margins. Retail expansion via generic production lowers barriers. The Indian Psychiatric Society reports 62% awareness growth (2024 survey). Unmet rural demand accelerates digital clinics.
- Addiction crisis boosts MDMA focus.
- Low-cost manufacturing advantages.
- 75% efficacy in pilot PTSD programs.
Competitive Landscape
Key players are expanding clinical trials to gain FDA approvals, addressing the 30% failure rate of traditional antidepressants. Phase 3 results in 2025 showed psilocybin achieving 80% remission in depression, boosting investor confidence. R&D funding hit US $1.2 Bn in 2024, fueled by regulatory support. Mergers and acquisitions are consolidating pipelines, though stricter EMA safety rules may raise compliance costs by 15%. Early entrants gain patent advantages, while latecomers risk challenges with saturated trial recruitment and higher operational barriers.
Key Companies
- Johnson & Johnson
- Jazz Pharmaceuticals
- COMPASS Pathways
- MindMed
- Cybin Inc.
- Psygen Labs
- Atai Life Science
- CaaMTech
- Mydecine Innovations Group
- Entheon Biomedical
- PharmaThera Biotech
- Seelos Therapeutics
Recent Developments:
- In February 2025, Jazz Pharmaceuticals reported record 2024 revenues of $4.1B, driven by strong growth in Xywav®, Epidiolex®, and oncology products. Key milestones include FDA approval and launch of Ziihera®, positive Phase 3 results for Zepzelca®, and continued expansion of its diversified portfolio, with 2025 revenue guidance set at $4.15–$4.40B.
- In October 2024, Johnson & Johnson will showcase 23 new studies at the 2024 Psych Congress, including long-term safety data on SPRAVATO® and insights into schizophrenia and depression. Key findings highlight relapse risks, treatment outcomes, and the burden of symptoms like anhedonia and insomnia.
- In December 2024, MindMed has dosed the first patient in its Phase 3 Voyage study of MM120 ODT (LSD) for generalized anxiety disorder, marking the first late-stage trial of its kind. The study builds on strong Phase 2b results and will evaluate safety and efficacy in around 200 participants, with topline data expected in the first half of 2026.
Global Psychedelic Drugs Market Segmentation-
By Product Type
- DMT
- Ketamine
- LSD
- MDMA
- Mescaline
- Psilocybin
By Therapeutic Indication
- Depression & Anxiety
- PTSD
- Drug & Alcohol dependence
By Route of Administration
- Oral
- Intranasal
- Intravenous
By Origin
- Natural
- Synthetic
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
1. Executive Summary
1.1. Global Psychedelic Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Fiver Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2024-2032
2.9.2. Price Impact Factors
3. Global Psychedelic Drugs Market Outlook, 2019 - 2032
3.1. Global Psychedelic Drugs Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
3.1.1. DMT
3.1.2. Ketamine
3.1.3. LSD
3.1.4. MDMA
3.1.5. Mescaline
3.1.6. Psilocybin
3.1.7. Misc.
3.2. Global Psychedelic Drugs Market Outlook, by Therapeutic Indication, Value (US$ Bn), 2019-2032
3.2.1. Depression & Anxiety
3.2.2. PTSD
3.2.3. Drug & Alcohol dependence
3.2.4. Misc.
3.3. Global Psychedelic Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
3.3.1. Oral
3.3.2. Intranasal
3.3.3. Intravenous
3.3.4. Misc.
3.4. Global Psychedelic Drugs Market Outlook, by Origin, Value (US$ Bn), 2019-2032
3.4.1. Natural
3.4.2. Synthetic
3.5. Global Psychedelic Drugs Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.5.1. North America
3.5.2. Europe
3.5.3. Asia Pacific
3.5.4. Latin America
3.5.5. Middle East & Africa
4. North America Psychedelic Drugs Market Outlook, 2019 - 2032
4.1. North America Psychedelic Drugs Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
4.1.1. DMT
4.1.2. Ketamine
4.1.3. LSD
4.1.4. MDMA
4.1.5. Mescaline
4.1.6. Psilocybin
4.1.7. Misc.
4.2. North America Psychedelic Drugs Market Outlook, by Therapeutic Indication, Value (US$ Bn), 2019-2032
4.2.1. Depression & Anxiety
4.2.2. PTSD
4.2.3. Drug & Alcohol dependence
4.2.4. Misc.
4.3. North America Psychedelic Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
4.3.1. Oral
4.3.2. Intranasal
4.3.3. Intravenous
4.3.4. Misc.
4.4. North America Psychedelic Drugs Market Outlook, by Origin, Value (US$ Bn), 2019-2032
4.4.1. Natural
4.4.2. Synthetic
4.5. North America Psychedelic Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.5.1. U.S. Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
4.5.2. U.S. Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
4.5.3. U.S. Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
4.5.4. U.S. Psychedelic Drugs Market Outlook, by Origin, 2019-2032
4.5.5. Canada Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
4.5.6. Canada Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
4.5.7. Canada Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
4.5.8. Canada Psychedelic Drugs Market Outlook, by Origin, 2019-2032
4.6. BPS Analysis/Market Attractiveness Analysis
5. Europe Psychedelic Drugs Market Outlook, 2019 - 2032
5.1. Europe Psychedelic Drugs Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
5.1.1. DMT
5.1.2. Ketamine
5.1.3. LSD
5.1.4. MDMA
5.1.5. Mescaline
5.1.6. Psilocybin
5.1.7. Misc.
5.2. Europe Psychedelic Drugs Market Outlook, by Therapeutic Indication, Value (US$ Bn), 2019-2032
5.2.1. Depression & Anxiety
5.2.2. PTSD
5.2.3. Drug & Alcohol dependence
5.2.4. Misc.
5.3. Europe Psychedelic Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
5.3.1. Oral
5.3.2. Intranasal
5.3.3. Intravenous
5.3.4. Misc.
5.4. Europe Psychedelic Drugs Market Outlook, by Origin, Value (US$ Bn), 2019-2032
5.4.1. Natural
5.4.2. Synthetic
5.5. Europe Psychedelic Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.5.1. Germany Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
5.5.2. Germany Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
5.5.3. Germany Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
5.5.4. Germany Psychedelic Drugs Market Outlook, by Origin, 2019-2032
5.5.5. Italy Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
5.5.6. Italy Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
5.5.7. Italy Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
5.5.8. Italy Psychedelic Drugs Market Outlook, by Origin, 2019-2032
5.5.9. France Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
5.5.10. France Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
5.5.11. France Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
5.5.12. France Psychedelic Drugs Market Outlook, by Origin, 2019-2032
5.5.13. U.K. Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
5.5.14. U.K. Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
5.5.15. U.K. Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
5.5.16. U.K. Psychedelic Drugs Market Outlook, by Origin, 2019-2032
5.5.17. Spain Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
5.5.18. Spain Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
5.5.19. Spain Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
5.5.20. Spain Psychedelic Drugs Market Outlook, by Origin, 2019-2032
5.5.21. Russia Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
5.5.22. Russia Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
5.5.23. Russia Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
5.5.24. Russia Psychedelic Drugs Market Outlook, by Origin, 2019-2032
5.5.25. Rest of Europe Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
5.5.26. Rest of Europe Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
5.5.27. Rest of Europe Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
5.5.28. Rest of Europe Psychedelic Drugs Market Outlook, by Origin, 2019-2032
5.6. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Psychedelic Drugs Market Outlook, 2019 - 2032
6.1. Asia Pacific Psychedelic Drugs Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
6.1.1. DMT
6.1.2. Ketamine
6.1.3. LSD
6.1.4. MDMA
6.1.5. Mescaline
6.1.6. Psilocybin
6.1.7. Misc.
6.2. Asia Pacific Psychedelic Drugs Market Outlook, by Therapeutic Indication, Value (US$ Bn), 2019-2032
6.2.1. Depression & Anxiety
6.2.2. PTSD
6.2.3. Drug & Alcohol dependence
6.2.4. Misc.
6.3. Asia Pacific Psychedelic Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
6.3.1. Oral
6.3.2. Intranasal
6.3.3. Intravenous
6.3.4. Misc.
6.4. Asia Pacific Psychedelic Drugs Market Outlook, by Origin, Value (US$ Bn), 2019-2032
6.4.1. Natural
6.4.2. Synthetic
6.5. Asia Pacific Psychedelic Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.5.1. China Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
6.5.2. China Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
6.5.3. China Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
6.5.4. China Psychedelic Drugs Market Outlook, by Origin, 2019-2032
6.5.5. Japan Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
6.5.6. Japan Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
6.5.7. Japan Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
6.5.8. Japan Psychedelic Drugs Market Outlook, by Origin, 2019-2032
6.5.9. South Korea Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
6.5.10. South Korea Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
6.5.11. South Korea Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
6.5.12. South Korea Psychedelic Drugs Market Outlook, by Origin, 2019-2032
6.5.13. India Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
6.5.14. India Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
6.5.15. India Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
6.5.16. India Psychedelic Drugs Market Outlook, by Origin, 2019-2032
6.5.17. Southeast Asia Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
6.5.18. Southeast Asia Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
6.5.19. Southeast Asia Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
6.5.20. Southeast Asia Psychedelic Drugs Market Outlook, by Origin, 2019-2032
6.5.21. Rest of SAO Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
6.5.22. Rest of SAO Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
6.5.23. Rest of SAO Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
6.5.24. Rest of SAO Psychedelic Drugs Market Outlook, by Origin, 2019-2032
6.6. BPS Analysis/Market Attractiveness Analysis
7. Latin America Psychedelic Drugs Market Outlook, 2019 - 2032
7.1. Latin America Psychedelic Drugs Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
7.1.1. DMT
7.1.2. Ketamine
7.1.3. LSD
7.1.4. MDMA
7.1.5. Mescaline
7.1.6. Psilocybin
7.1.7. Misc.
7.2. Latin America Psychedelic Drugs Market Outlook, by Therapeutic Indication, Value (US$ Bn), 2019-2032
7.2.1. Depression & Anxiety
7.2.2. PTSD
7.2.3. Drug & Alcohol dependence
7.2.4. Misc.
7.3. Latin America Psychedelic Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
7.3.1. Oral
7.3.2. Intranasal
7.3.3. Intravenous
7.3.4. Misc.
7.4. Latin America Psychedelic Drugs Market Outlook, by Origin, Value (US$ Bn), 2019-2032
7.4.1. Natural
7.4.2. Synthetic
7.5. Latin America Psychedelic Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.5.1. Brazil Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
7.5.2. Brazil Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
7.5.3. Brazil Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
7.5.4. Brazil Psychedelic Drugs Market Outlook, by Origin, 2019-2032
7.5.5. Mexico Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
7.5.6. Mexico Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
7.5.7. Mexico Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
7.5.8. Mexico Psychedelic Drugs Market Outlook, by Origin, 2019-2032
7.5.9. Argentina Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
7.5.10. Argentina Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
7.5.11. Argentina Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
7.5.12. Argentina Psychedelic Drugs Market Outlook, by Origin, 2019-2032
7.5.13. Rest of LATAM Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
7.5.14. Rest of LATAM Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
7.5.15. Rest of LATAM Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
7.5.16. Rest of LATAM Psychedelic Drugs Market Outlook, by Origin, 2019-2032
7.6. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Psychedelic Drugs Market Outlook, 2019 - 2032
8.1. Middle East & Africa Psychedelic Drugs Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
8.1.1. DMT
8.1.2. Ketamine
8.1.3. LSD
8.1.4. MDMA
8.1.5. Mescaline
8.1.6. Psilocybin
8.1.7. Misc.
8.2. Middle East & Africa Psychedelic Drugs Market Outlook, by Therapeutic Indication, Value (US$ Bn), 2019-2032
8.2.1. Depression & Anxiety
8.2.2. PTSD
8.2.3. Drug & Alcohol dependence
8.2.4. Misc.
8.3. Middle East & Africa Psychedelic Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
8.3.1. Oral
8.3.2. Intranasal
8.3.3. Intravenous
8.3.4. Misc.
8.4. Middle East & Africa Psychedelic Drugs Market Outlook, by Origin, Value (US$ Bn), 2019-2032
8.4.1. Natural
8.4.2. Synthetic
8.5. Middle East & Africa Psychedelic Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.5.1. GCC Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
8.5.2. GCC Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
8.5.3. GCC Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
8.5.4. GCC Psychedelic Drugs Market Outlook, by Origin, 2019-2032
8.5.5. South Africa Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
8.5.6. South Africa Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
8.5.7. South Africa Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
8.5.8. South Africa Psychedelic Drugs Market Outlook, by Origin, 2019-2032
8.5.9. Egypt Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
8.5.10. Egypt Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
8.5.11. Egypt Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
8.5.12. Egypt Psychedelic Drugs Market Outlook, by Origin, 2019-2032
8.5.13. Nigeria Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
8.5.14. Nigeria Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
8.5.15. Nigeria Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
8.5.16. Nigeria Psychedelic Drugs Market Outlook, by Origin, 2019-2032
8.5.17. Rest of Middle East Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
8.5.18. Rest of Middle East Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
8.5.19. Rest of Middle East Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
8.5.20. Rest of Middle East Psychedelic Drugs Market Outlook, by Origin, 2019-2032
8.6. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2024
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Johnson & Johnson
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Jazz Pharmaceuticals
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Developments
9.4.3. COMPASS Pathways
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Developments
9.4.4. MindMed
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Developments
9.4.5. Cybin Inc.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Developments
9.4.6. Psygen Labs
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Developments
9.4.7. Atai Life Science
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Developments
9.4.8. CaaMTech
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Developments
9.4.9. Mydecine Innovations Group
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Developments
9.4.10. Entheon Biomedical
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Developments
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations
|
BASE YEAR |
HISTORICAL DATA |
FORECAST PERIOD |
UNITS |
|||
 |
2024 |
 |
2019 - 2024 |
 |
2025 - 2032 |
Value: US$ Billion |
|
REPORT FEATURES |
DETAILS |
|
Product Type Coverage |
|
|
Therapeutic Indication Coverage |
|
|
Route of Administration Coverage |
|
|
Origin Coverage |
|
|
Geographical Coverage |
|
|
Leading Companies |
|
|
Report Highlights |
Key Market Indicators, Macro-micro economic impact analysis, Technological Roadmap, Key Trends, Driver, Restraints, and Future Opportunities & Revenue Pockets, Porter’s 5 Forces Analysis, Historical Trend (2019-2024), Market Estimates and Forecast, Market Dynamics, Industry Trends, Competition Landscape, Category, Region, Country-wise Trends & Analysis, COVID-19 Impact Analysis (Demand and Supply Chain) |
Quality assured
